rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NVS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Here’s How Much You Would Have Made Owning Novartis Stock In The Last 5 Years
      11h agoBenzingaNVS
      FDA Clears Novartis Drug Cosentyx As Steroid Alternative for Inflammatory Pain Causing Stiff Shoulders
      Nov 17Yahoo FinanceNVS
      Novartis' Cosentyx wins FDA approval for polymyalgia rheumatica (NVS:NYSE)
      Nov 17Seeking AlphaNVS
      Novartis Receives FDA Approval for Cosentyx in Polymyalgia Rheumatica
      Nov 17Yahoo FinanceNVS
      Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica
      Nov 17Investing.comNVS
      How Investors Are Reacting To Novartis (SWX:NOVN) Drug Approval Progress
      Nov 16Yahoo FinanceNVS
      Novartis (SWX:NOVN), What Is Behind The Fresh Attention?
      Nov 16Yahoo FinanceNVS
      Novartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS
      Nov 16Yahoo FinanceNVS
      Is Novartis (NVS) Outperforming Other Medical Stocks This Year?
      Nov 16Yahoo FinanceNVS
      Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
      Nov 13Yahoo FinanceNVS
      Novartis eyes Rhapsido’s broader use on positive urticaria data drop
      Nov 13Yahoo FinanceNVS
      Merck KGaA Drops Heart Drug as Novartis Trial Flop Sows Doubts
      Nov 12BloombergMRKNVS
      Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice
      Nov 12Yahoo FinanceNVS
      Astrosalva Therapeutics Adds Michael MacLean, Former CFO of Novartis-Acquired Avidity Biosciences, to Strategic Advisory Board
      Nov 12MorningstarRNANVS
      Is Novartis (SWX:NOVN) A Bargain Or Fully Priced Now?
      Nov 11Yahoo FinanceNVS
      Novartis (SWX:NOVN) Halts Pelacarsen After Trial Miss As Ianalumab Data Impresses
      Nov 11Yahoo FinanceNVS
      How Amgen, In A Buy Zone, Is Taking On Novartis With A First-Ever

      Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's.

      Nov 11Investor's Business DailyAMGNNVS
      Novartis releases long-term data for ianalumab in Sjögren’s disease

      Novartis says continuous monthly ianalumab cut Sjögren’s disease activity by 7.5 ESSDAI points at week 108. Read more here.

      Nov 10Seeking AlphaNVS
      How Stock Of The Day TG Therapeutics Is Making Waves For Its Rivals

      Shares raced through a buy zone but are range of an alternate entry.

      Nov 10Investor's Business DailyTGTXNVS
      Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity

      Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings1 Nearly two-thirds of patients on continuous ianalumab reached low disease activity at Week 1081 Improvements in stimulated salivary flow were maintained in patients with baseline salivary flow >0.4mL/min continuing ianalumab1 Patients who switched from placebo to ianalumab monthly saw improvements across most efficacy outcomes, including an increase in low disease act

      Nov 10Yahoo FinanceNVS
      Novartis ranks first place in 2026 Access to Medicine Index

      Novartis retains first place ranking among 20 sector peers for efforts to improve access to medicinesFirst company to achieve No. 1 rank across all Technical Areas since Index began in 2008, achieving R&D score almost twice the sector averageRecognizes progress to expand care for cancer and heart disease, Coartem® Baby, and next-gen antimalarial KLU156 (ganaplacide/lumefantrine) Basel, November 10, 2026 – Novartis today announced the company has ranked first place in the 2026 Access to Medicine

      Nov 10Yahoo FinanceNVS
      Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer

      LLY, NVS and BAYRY stand out as the pharma sector rebounds in 2026, supported by innovative drug pipelines, strong product demand and rising earnings estimates.

      Nov 10Yahoo FinanceLLYNVS
      Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
      Nov 7Seeking AlphaIONSNVS
      Novartis shelves potential blockbuster pelacarsen as landmark study fails
      Nov 7Investing.comNVS
      Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
      Nov 7ReutersNVONVS
      Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
      Nov 7CNNNVS
      How Cardiologists’ High Hopes for Two Drugs Were Dashed
      Nov 7The New York TimesNVONVS
      Novartis Abandons Heart Drug After Surprising Failure in Key Study
      Nov 7BloombergNVS
      The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke

      The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?

      Nov 7NBC NewsNVS
      US regulator investigates tumour risk in children given Novartis gene therapy

      FDA says Zolgensma’s benefits still outweigh risks, but weighs action after nine tumour cases emerge among 6,000 treated infants.

      Nov 7South China Morning PostNVS
      Two tumour cases in children linked to SMA drug, Novartis says
      Nov 6ReutersNVS
      Novartis Says Tumors Found in Children Given SMA Gene Therapy
      Nov 6BloombergNVS
      $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today
      Nov 5BenzingaNVS
      Novartis stock slips amid Zolgensma safety concerns (NVS:NYSE)

      Novartis (NVS) stock drops as the company faces fresh safety concerns over Zolgensma gene therapy after reports of tumors found in treated children. Read more here.

      Nov 5Seeking AlphaNVS
      Novartis: 3 Key Takeaways for Long-Term Investors | The Motley Fool

      Operating margins are on track to hit 40% by 2029 as cost discipline accelerates alongside new drug launches.

      Nov 4The Motley FoolNVS
      BioArctic collaborator Novartis terminates agreement
      Nov 2Yahoo FinanceNVS
      Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
      Nov 2ReutersNVS
      Deutsche Bank turns bearish on Novartis as shares recover failed trial losses
      Nov 2Investing.comDBNVS
      Deutsche Bank downgrades Novartis stock rating to sell on valuation
      Nov 2Investing.comNVS
      Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial
      Nov 2Yahoo FinanceNVS
      Companies promised AI gains — here's how the payoff showed up in earnings

      Santander, Novartis and other companies say AI is beginning to boost revenue, cut costs or improve profitability as investors seek returns.

      Nov 1CNBCNVSSAN
      Anthropic's next big AI business is life sciences, from biotech research to drug discovery

      Anthropic's S-1 filing says Claude can accelerate drug discovery and biology research, making life sciences central to the AI company's IPO pitch.

      Oct 31Business InsiderNVS
      Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach (NVS)
      Oct 31Seeking AlphaNVS
      All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
      Oct 30Yahoo FinanceNVS
      A pharma giant is moving past one patent cliff — but another is already looming

      Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.

      Oct 30CNBCNVS
      China Upends Global Drug Development With Cheap and Rapid Human Trials
      Oct 29BloombergAZNNVS
      Lilly shuffles business structure; Novartis writes off part of Avidity deal
      Oct 28Yahoo FinanceLLYNVS
      Novartis initiates phase 2 study of MRT-6160 for psoriatic arthritis
      Oct 28Investing.comNVS
      Novartis (SWX:NOVN) Stock Faces Q3 Earnings Squeeze After Profit Slump
      Oct 28Yahoo FinanceNVS
      The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailNVS

      This is the newest page. Registered accounts read further back.